Bachem Holding AG Stock price

Equities

BANB

CH1176493729

Biotechnology & Medical Research

Delayed Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
86.4 CHF +2.19% Intraday chart for Bachem Holding AG +2.80% +32.92%
Sales 2024 * 618M 685M Sales 2025 * 823M 912M Capitalization 6.48B 7.18B
Net income 2024 * 127M 141M Net income 2025 * 160M 177M EV / Sales 2024 * 10.4 x
Net cash position 2024 * 78.09M 86.55M Net Debt 2025 * 28.4M 31.48M EV / Sales 2025 * 7.91 x
P/E ratio 2024 *
51.6 x
P/E ratio 2025 *
40.2 x
Employees 2,006
Yield 2024 *
1%
Yield 2025 *
1.04%
Free-Float 94.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.19%
1 week+2.80%
Current month+23.43%
1 month+22.81%
3 months+32.11%
6 months+27.43%
Current year+32.92%
More quotes
1 week
83.25
Extreme 83.25
86.50
1 month
68.20
Extreme 68.2
86.50
Current year
53.95
Extreme 53.95
86.50
1 year
53.95
Extreme 53.95
105.60
3 years
49.90
Extreme 49.9
171.00
5 years
23.00
Extreme 23
171.00
10 years
8.31
Extreme 8.31
171.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 18-12-31
Director of Finance/CFO 47 21-01-31
Chief Tech/Sci/R&D Officer - 02-12-31
Members of the board TitleAgeSince
Director/Board Member 82 -
Chairman 68 12-04-24
Director/Board Member 51 11-04-12
More insiders
Date Price Change Volume
24-03-28 86.4 +2.19% 59,573
24-03-27 84.55 -0.59% 57,551
24-03-26 85.05 +0.12% 86,630
24-03-25 84.95 +2.10% 66,469
24-03-22 83.2 -1.01% 63,597

Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT

More quotes
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
6
Last Close Price
86.4 CHF
Average target price
70.8 CHF
Spread / Average Target
-18.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Bachem Holding AG - Swiss Exchange